Armor Collaborates with Digital Healthcare Communications Company to Protect Critical Healthcare Applications, Sensitive Patient Data
Healthcare data is one of the most popular targets for today’s savvy threat actors. To defend against these advanced threats — and proactively maintain HIPAA and ISO 27001 compliance — xmachina selects Armor to secure a mass-scale healthcare application for one of their major international pharmaceutical customers. Armor, a leader in active cyber defense, strengthens cloud-based security environments for global organizations.
The patient-focused application, which leads the physical therapy industry, streamlines medication treatments and communication with doctors or nurses. Understanding the importance of ISO 13485 requirements, xmachina operates the application, which is self-administered by patients and supports their therapy. The program requires patients to have a secure method of capturing and submitting data.
To support this innovative functionality, xmachina chose Armor Complete because of Armor’s focus on providing secure and compliant managed cloud experiences for its customers. Armor Complete, which is powered by Armor’s proven and secure Virtual Private Cloud (VPC), is the ideal solution for organizations that store, access or manage critical or sensitive data that requires the best in security architecture, performance and service.
Healthcare organizations are among Armor’s largest and most loyal customers. As the managed security provider for four of the top 10 healthcare SaaS companies, Armor is trusted by healthcare organizations for their security-first solutions and understanding of industry compliance.
Armor scales and applies security controls based on learnings from protecting a global customer environment. The company develops its threat intelligence from more than 800,000 open research sources and a worldwide proprietary honeypot network.
- xmachina, who was working in conjunction with the pharmaceutical manufacturer, conducted a global search for an effective secure cloud environment.
- Armor Complete was able to deliver the required secure global footprint with ISO 27001 certification, and also was capable of supporting HIPAA compliance, which was non-negotiable.
- xmachina’s quality management system is certified according to EN ISO 13485. This is why the digital agency and healthcare expert is approved to develop and operate software and apps in the healthcare market.
Mark Kornegay, SVP Global Sales and Channels | Armor
“The relationship with xmachina is another instance of how deeply rooted Armor is in delivering both secure and compliant managed cloud services. The secure portal that xmachina is operating for patients self-administering drugs is very forward-thinking. We’re proud to have engaged with a company taking such strides in the healthcare community.”
Klaus Mueller, CEO | xmachina – Advancing E-Health
“While we’ve seen a massive uptick in the use of healthcare applications being used by both healthcare professionals and patients, it is our mission to advance the e-health industry. Our patient-accessible portal is one example of our innovative, customer-centric approach to healthcare. The cooperation with Armor allows us to stay flexible and respond quickly to changes, such as the dynamic nature of application traffic. It has been a pleasure working with Armor in an industry that can be very difficult to navigate. It puts us at ease knowing that Armor offers the best in the business when it comes to managing security and compliance risks in the cloud.”
xmachina is synonymous for trendsetting e-health solutions, medical software, healthcare apps and health marketing. With an experienced team of consultants, developers and creative minds, xmachina implements processes that bring the messages to the relevant target groups with state-of-the-art technology and which simultaneously fulfil the high pharmaceutical standards – all since 1997. xmachina’s quality management system is certified according to EN ISO 13485. For more information, visit: https://www.xmachina.de/international-visitors/
The leader in active cyber defense, Armor offers customer-centric security outcomes for retail and eCommerce enterprises, healthcare organizations, payment leaders and financial institutions. Armor protects highly sensitive data for the most security-conscious companies in the world. With its proven cybersecurity approach and proprietary cloud infrastructure built specifically for security, compliance and performance, responsible businesses choose Armor to reduce their risk. For more information, visit armor.com or call 1-844-682-2858.
Voce Communications for Armor
Melissa Felton, 330-401-9220
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom